<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04455633</url>
  </required_header>
  <id_info>
    <org_study_id>LX9211.1-201-DPN</org_study_id>
    <secondary_id>LX9211.201</secondary_id>
    <nct_id>NCT04455633</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and PK of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain</brief_title>
  <acronym>RELIEF-DPN 1</acronym>
  <official_title>A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of LX9211 in the Treatment of Diabetic Peripheral Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexicon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lexicon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the efficacy of a low and high dose of LX9211 compared to placebo in reducing
      pain related to diabetic peripheral neuropathy over an 11 week assessment period.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Average Daily Pain Score (ADPS)</measure>
    <time_frame>Day 1 to Week 6</time_frame>
    <description>The change from Baseline (Day 1) to Week 6 in Average Daily Pain Score (ADPS), based on the 11-point numerical rating scale (NRS) (0 [no pain] to 10 [worst imaginable pain])</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>≥30% reduction in pain intensity</measure>
    <time_frame>Day 1 to Week 6</time_frame>
    <description>Proportion of patients with ≥30% reduction in pain intensity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>≥50% reduction in pain intensity</measure>
    <time_frame>Day 1 to Week 6</time_frame>
    <description>Proportion of patients with ≥50% reduction in pain intensity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: # of AEs reported</measure>
    <time_frame>Day 1 to Week 6</time_frame>
    <description># of Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">282</enrollment>
  <condition>Diabetic Peripheral Neuropathy</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>LX9211 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LX9211, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LX9211 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LX9211, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX9211 low dose</intervention_name>
    <description>11-week assessment period</description>
    <arm_group_label>LX9211 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX9211 high dose</intervention_name>
    <description>11-week assessment period</description>
    <arm_group_label>LX9211 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX9211 Placebo</intervention_name>
    <description>11-week assessment period</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has given written informed consent to participate in the study in accordance
             with local regulations

          -  Adult male and female (surgically sterile or postmenopausal) patients ≥18 to ≤75 years
             of age at the time of screening

          -  Body mass index ≥18.0 to ≤40.0 kg/m2 at Screening

          -  Diagnosis of DPNP at Screening

          -  Pain from DPN ranging between at least 6 months to no more than 5 years in duration

          -  A1C ≤10.5% at screening

          -  Stable regimen for the treatment of T1DM or T2DM for ≥1 month prior to Screening

        Exclusion Criteria:

          -  Presence of other painful conditions that may confound assessment or self-evaluation
             of DPNP

          -  History of major depressive episode, active, significant psychiatric disorders

          -  History of clinically significant drug or alcohol use disorder

          -  History of neurolytic or neurosurgical therapy for DPNP

          -  Use of opioid medications for management of DPNP within the 6 months prior to
             Screening Visit

          -  Use of chronic NSAIDs for management of DPNP within the 3 months prior to the
             Screening Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suman Wason, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lexicon Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chris Warner</last_name>
    <phone>(281)863-3000</phone>
    <email>cwarner@lexpharma.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>June 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2020</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

